AU2002240033B2 - Anti-bacterial vaccine compositions - Google Patents

Anti-bacterial vaccine compositions Download PDF

Info

Publication number
AU2002240033B2
AU2002240033B2 AU2002240033A AU2002240033A AU2002240033B2 AU 2002240033 B2 AU2002240033 B2 AU 2002240033B2 AU 2002240033 A AU2002240033 A AU 2002240033A AU 2002240033 A AU2002240033 A AU 2002240033A AU 2002240033 B2 AU2002240033 B2 AU 2002240033B2
Authority
AU
Australia
Prior art keywords
virulence
seq
gene
dna
multocida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002240033A
Other languages
English (en)
Other versions
AU2002240033A1 (en
Inventor
Troy E. Fuller
Michael J. Kennedy
David E. Lowery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2002240033A1 publication Critical patent/AU2002240033A1/en
Application granted granted Critical
Publication of AU2002240033B2 publication Critical patent/AU2002240033B2/en
Assigned to ZOETIS P&U LLC reassignment ZOETIS P&U LLC Request to Amend Deed and Register Assignors: PHARMACIA & UPJOHN COMPANY
Assigned to ZOETIS SERVICES LLC reassignment ZOETIS SERVICES LLC Request to Amend Deed and Register Assignors: ZOETIS P&U LLC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002240033A 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions Expired AU2002240033B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions
US09/809,665 2001-03-15
PCT/US2002/001971 WO2002075507A2 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Publications (2)

Publication Number Publication Date
AU2002240033A1 AU2002240033A1 (en) 2003-03-27
AU2002240033B2 true AU2002240033B2 (en) 2007-11-08

Family

ID=25201919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002240033A Expired AU2002240033B2 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Country Status (18)

Country Link
US (2) US6790950B2 (enExample)
EP (1) EP1368456B1 (enExample)
JP (2) JP2005502315A (enExample)
AR (2) AR035745A1 (enExample)
AT (1) ATE500316T1 (enExample)
AU (1) AU2002240033B2 (enExample)
CA (2) CA2852293A1 (enExample)
CY (1) CY1112014T1 (enExample)
DE (1) DE60239318D1 (enExample)
DK (1) DK1368456T3 (enExample)
ES (1) ES2362041T3 (enExample)
MX (1) MXPA03008296A (enExample)
NZ (1) NZ528208A (enExample)
PE (1) PE20021008A1 (enExample)
PT (1) PT1368456E (enExample)
SI (1) SI1368456T1 (enExample)
TW (4) TWI335934B (enExample)
WO (1) WO2002075507A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060116041A (ko) * 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
CA2729818A1 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015066292A1 (en) * 2013-11-01 2015-05-07 Merial Limited Attenuated pasteurella multocidavaccines & methods of making & use thereof
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
SK55593A3 (en) 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
WO1994011024A1 (en) 1992-11-06 1994-05-26 Regents Of The University Of Minnesota Composition protective against p. multocida pasteurellosis infection
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
DE19502584C2 (de) 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
ATE419371T1 (de) * 1996-09-06 2009-01-15 Jensen Peter Ruhdal Verfahren zur verbesserung der herstellung eines erwünschten produktes aus einer zelle
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
KR20060116041A (ko) 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CA2379119A1 (en) * 1999-07-12 2001-01-18 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
EP1278768B1 (en) * 2000-04-27 2006-11-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
DK1368456T3 (da) 2011-05-23
DE60239318D1 (de) 2011-04-14
TWI335935B (en) 2011-01-11
TW200916577A (en) 2009-04-16
AR071888A2 (es) 2010-07-21
US7476391B2 (en) 2009-01-13
TWI335934B (en) 2011-01-11
WO2002075507A3 (en) 2003-09-12
TW201040261A (en) 2010-11-16
JP2011097938A (ja) 2011-05-19
EP1368456A2 (en) 2003-12-10
TWI328035B (en) 2010-08-01
NZ528208A (en) 2008-04-30
MXPA03008296A (es) 2007-05-28
US20040110268A1 (en) 2004-06-10
US20050003512A1 (en) 2005-01-06
PE20021008A1 (es) 2002-11-13
CY1112014T1 (el) 2015-11-04
US6790950B2 (en) 2004-09-14
ES2362041T3 (es) 2011-06-27
PT1368456E (pt) 2011-06-01
SI1368456T1 (sl) 2011-06-30
CA2438315C (en) 2014-09-02
EP1368456B1 (en) 2011-03-02
WO2002075507A2 (en) 2002-09-26
JP2005502315A (ja) 2005-01-27
CA2852293A1 (en) 2002-09-26
ATE500316T1 (de) 2011-03-15
TW201040262A (en) 2010-11-16
WO2002075507B1 (en) 2003-12-11
TWI334884B (en) 2010-12-21
CA2438315A1 (en) 2002-09-26
AR035745A1 (es) 2004-07-07

Similar Documents

Publication Publication Date Title
US9289486B2 (en) Attenuated fhaC mutants of Pasteurellaceae bacteria and vaccine compositions thereof
CA2438315C (en) Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom
AU2002240033A1 (en) Anti-bacterial vaccine compositions
CA2815566C (en) Pasteurellaceae bacteria comprising a mutated virulence gene and an anti-bacterial vaccine prepared therefrom
AU2007242960B2 (en) Anti-bacterial vaccine compositions
AU2013201267B2 (en) Anti-bacterial vaccine compositions
AU2010201539C1 (en) Anti-bacterial vaccine compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired